Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: Organovo Holdings, Inc. vs. Intuitive Surgical

By Keith Speights - Apr 15, 2016 at 1:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two companies with ground-breaking healthcare technology. Which is the better choice for investors?

Image source: Intuitive Surgical.

Any list of technologies that could revolutionize healthcare would be incomplete without 3D bioprinting and robotic surgical systems. And any discussion of those two revolutionary technologies would be lacking without mention of a couple of companies: Organovo Holdings (ONVO -11.47%) and Intuitive Surgical (ISRG 0.43%). Both companies' stocks have taken investors on an up-and-down ride over the past several years. But which healthcare pioneer is the better buy now? 

3D view of the future
Imagine artificial human tissue used to test experimental drugs. Picture bioengineered tissues being implanted into human bodies to replace diseased tissues. With Organovo, these scenarios don't require much imagination. The company is already using 3D bioprinting technology to make them a reality.

Organovo currently claims one commercial product -- exVive3D human liver tissue. Although exVive3D broke new ground as the first 3D bioprinted human tissue on the market, the product hasn't exactly been a huge financial winner so far. Organovo made less than $300,000 in revenue last quarter from the liver tissue.

It's still early, though. Organovo expects additional studies that suggest advantages for using bioprinted liver tissues in drug testing could help drive higher adoption. The company continues to educate potential customers about 3D bioprinting. Organovo CEO Keith Murphy recently noted that customers don't usually say no but instead say, "Come back when you can show me more."

A second product should be on the market soon. Organovo developed a bioprinted human kidney tissue that is on track for commercialization in the third quarter of 2016. 

Organovo's executive team thinks annual revenue of over $100 million is achievable in the future. No one knows for sure, though, how long it might take for that future to arrive. In the meantime, the company is losing upwards of $10 million per quarter. Organovo reported $70 million in cash and cash equivalents as of the end of 2015. It's likely that the company will have to generate more cash not too far down the road.

Robot dreams
You wouldn't have to go back too many years for any talk about robotic surgical systems to be laughed off as the stuff of science fiction. However, over 3 million procedures have been performed across the world using Intuitive Surgical's da Vinci robot-assisted surgical systems.

Unlike Organovo, Intuitive Surgical has been profitable for quite a while. The company made nearly $589 million in earnings last year on $2.38 billion in revenue. Not everything has been rosy for Intuitive Surgical, though.

The stock plunged in 2013 over concerns that the benefits of using robotic surgery didn't justify the higher costs. It took three years for Intuitive's shares to climb back to early 2013 levels. So what are the prospects now for the company?

Probably the best sign for Intuitive Surgical is that the number of procedures using its da Vinci systems is growing at a solid double-digit annual percentage. The company is expanding its focus from hysterectomies and prostatectomies to also include colorectal surgery and hernia repair. And Intuitive appears to be doing a pretty good job of making the case that its solutions are cost-effective.

From a financial perspective, Intuitive Surgical appears to be in great shape. It reported $3.3 billion in cash, cash equivalents, and investments as of the end of 2015. It also has no debt. 

Better buy
Although Organovo's bioprinting technology is intriguing, there's no doubt at all which of these stocks is the better pick. Intuitive Surgical stands out as the clear winner.

One comparison tells the tale. Organovo hopes to someday reach annual sales of $100 million. Intuitive Surgical grew its cash stockpile by more than twice that amount in just the fourth quarter of 2015.

Intuitive Surgical's stock isn't exactly cheap, currently trading at nearly 27 times forward earnings. With that kind of premium valuation, any big missteps could cause shares to fall hard. Still, though, the future appears to be bright for the company. Intuitive Surgical CEO Gary Guthart thinks that robotic assisted surgery "is in its infancy." If he's right, Intuitive should continue to play a role in revolutionizing healthcare for years to come.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
$219.07 (0.43%) $0.93
Organovo Holdings, Inc. Stock Quote
Organovo Holdings, Inc.
$2.47 (-11.47%) $0.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.